Today: 7 February 2026
Subscribe
Browse Category

NYSE:PFE News 22 December 2025 - 29 December 2025

Pfizer stock today: PFE edges down as Wall Street looks to Feb. 3 results update

Pfizer stock today: PFE edges down as Wall Street looks to Feb. 3 results update

NEW YORK, December 29, 2025, 2:08 PM ET — Regular session Pfizer shares dipped slightly on Monday, trading down about 0.1% at $25.06 as of 2:08 p.m. ET. The stock has moved between $24.99 and $25.19 in the regular session. The muted move matters because liquidity is thinning into year-end, leaving defensive names like large drugmakers more sensitive to sector headlines and positioning. Reuters reported trading volumes were expected to be light this week, with U.S. markets shut on Thursday for New Year’s Day. Reuters For Pfizer, the backdrop is still its long-dated reset story: investors are weighing whether its
29 December 2025
·····
Pfizer filings spotlight big portfolio shifts as Live Oak slashes stake 92%

Pfizer filings spotlight big portfolio shifts as Live Oak slashes stake 92%

NEW YORK, December 29, 2025, 10:35 ET Live Oak Private Wealth LLC cut its stake in Pfizer (PFE.N) by 92.5% in the third quarter, selling 216,868 shares and ending the period with 17,627 shares, a regulatory filing showed. MarketBeat+2SEC+2 The disclosures matter because quarterly holdings reports are one of the few windows investors get into how money managers were positioned in major stocks heading into the final stretch of the year. The filings can signal shifting conviction in Pfizer, a high-profile name in U.S. healthcare. MarketBeat+2MarketBeat+2 The reports are known as Form 13F filings, which large investment managers submit to
29 December 2025
·····
Pfizer stock holds near $25 as Wall Street waits for the next big catalyst

Pfizer stock holds near $25 as Wall Street waits for the next big catalyst

NEW YORK, December 28, 2025, 23:32 ET — Market closed. Pfizer Inc shares edged higher in the last U.S. session, closing Friday up 0.24% at $25.09. The stock traded between $24.92 and $25.11 on the day. Investing.com The modest move leaves Pfizer in the mid-$20s, as investors weigh whether the drugmaker can stabilize revenue after a December reset of expectations for 2026. The next scheduled catalyst is the company’s Feb. 3 quarterly update. Pfizer+1 Pfizer said on Dec. 16 it expects 2026 revenue of $59.5 billion to $62.5 billion and adjusted diluted earnings of $2.80 to $3.00 per share. “Adjusted”
29 December 2025
·····
Pfizer Stock (NYSE: PFE) Holds Near $25 as Markets Close for the Weekend: Latest News, Analyst Targets, and What to Watch Monday

Pfizer Stock (NYSE: PFE) Holds Near $25 as Markets Close for the Weekend: Latest News, Analyst Targets, and What to Watch Monday

NEW YORK, Dec. 28, 2025, 2:50 p.m. ET — U.S. stock market closed (Sunday). Pfizer Inc. (NYSE: PFE) heads into the final week of 2025 with its shares hovering in the mid-$20s — a level Wall Street has increasingly framed as a “show-me” zone for investors who want evidence that Pfizer can navigate the post-COVID comedown and looming patent expirations while rebuilding growth through oncology and obesity-focused deals. With U.S. exchanges closed for the weekend, the most actionable information for investors is where Pfizer last finished the regular session, what (limited) fresh weekend reading emerged over the past 24–48 hours,
28 December 2025
·····
Pfizer Stock (PFE) Update: Shares Hold Near $25 Into Year-End as Investors Weigh 2026 Guidance, Dividend, and Pipeline Catalysts

Pfizer Stock (PFE) Update: Shares Hold Near $25 Into Year-End as Investors Weigh 2026 Guidance, Dividend, and Pipeline Catalysts

NEW YORK, Dec. 27, 2025, 3:07 p.m. ET — Market closed Pfizer Inc. (NYSE: PFE) is heading into the final trading days of 2025 with its stock still anchored in the mid-$20s, a range that has increasingly defined sentiment around the pharmaceutical giant as Wall Street debates two competing narratives: near-term pressure from fading COVID-era revenues and patent expirations, versus a longer-term rebuild driven by oncology and newer growth categories such as obesity. With U.S. equities closed for the weekend, investors won’t see fresh price discovery until Monday’s opening bell. That matters in a holiday-thinned tape—one where broad indexes have
27 December 2025
·····
Pfizer (PFE) Stock News, Forecasts and Analyst Outlook as of Dec. 25, 2025

Pfizer (PFE) Stock News, Forecasts and Analyst Outlook as of Dec. 25, 2025

Pfizer Inc. (NYSE: PFE) heads into Christmas Day with investors digesting a dense run of December headlines: a 2026 outlook that came in below Wall Street expectations, ongoing restructuring and cost-cutting, fresh U.S. drug-pricing initiatives that could reshape the industry’s economics, and multiple pipeline updates spanning oncology, immunology and cardiometabolic disease. U.S. markets are closed on Thursday, Dec. 25, 2025, but Pfizer shares last traded on Wednesday, Dec. 24 at $25.03, after moving between $24.90 and $25.14 intraday, according to the latest available pricing data. Below is a detailed look at the current news, forward guidance, and sell-side forecasts shaping
25 December 2025
·····
Pfizer Stock (PFE) After Hours Today, Dec. 24, 2025: Why Shares Rose in the Christmas Eve Session and What to Watch Before the Next Market Open

Pfizer Stock (PFE) After Hours Today, Dec. 24, 2025: Why Shares Rose in the Christmas Eve Session and What to Watch Before the Next Market Open

Pfizer, Inc. (NYSE: PFE) ended the trading day higher on Wednesday, December 24, 2025—an early-close session for U.S. equities ahead of Christmas—before holding essentially flat in after-hours trading. The move may look modest on the surface, but it lands at a moment when Pfizer’s stock narrative is unusually “headline-sensitive”: investors are balancing near-term safety scrutiny around a newly approved hemophilia medicine, management’s fresh 2026 outlook, and the longer-running debate over how Pfizer bridges a looming patent cliff with an oncology- and obesity-focused pipeline. PFE stock price after the bell: the closing print and after-hours check-in Here’s the end-of-day snapshot investors
24 December 2025
····
Pfizer (PFE) Stock News Today: 2026 Guidance, Drug-Price Deals, Pipeline Catalysts, and Analyst Forecasts (Dec. 24, 2025)

Pfizer (PFE) Stock News Today: 2026 Guidance, Drug-Price Deals, Pipeline Catalysts, and Analyst Forecasts (Dec. 24, 2025)

Pfizer Inc. (NYSE: PFE) stock is spending Christmas Eve in the familiar “mid-$20s” zone — a level that has become a psychological battleground for investors trying to decide whether Pfizer is a high-yield value play, a turnaround story, or simply a “show-me” stock until growth returns. As of Dec. 24, 2025, Pfizer shares were trading around $25 in holiday-thinned markets, leaving the company with a market capitalization of roughly $142 billion and keeping the conversation laser-focused on one question: Can Pfizer rebuild durable growth after the COVID-era revenue boom — and ahead of a looming patent cliff and intensifying U.S.
24 December 2025
·····
Pfizer Stock (PFE) on Dec. 24, 2025: Latest News, 2026 Guidance, Dividend, and Analyst Forecasts

Pfizer Stock (PFE) on Dec. 24, 2025: Latest News, 2026 Guidance, Dividend, and Analyst Forecasts

NEW YORK — Pfizer Inc. (NYSE: PFE) is heading into the year-end stretch with investors juggling two competing storylines: near-term pressure from fading COVID-era sales and looming patent expirations, versus a long-term rebuild powered by oncology, internal medicine, and a refreshed pipeline strategy. In holiday-thinned trading on December 24, 2025, Pfizer shares were around $24.93. That “mid‑$20s” level matters because it has become the market’s psychological waiting room: bulls see a discounted global pharma franchise with a large dividend and multiple pipeline shots on goal; bears see a company still searching for its next era-defining growth engine. What’s moving Pfizer
24 December 2025
·····
Pfizer (PFE) Stock After Hours: What’s Moving Shares After the Dec. 23, 2025 Close—and What to Watch Before Dec. 24’s Open

Pfizer (PFE) Stock After Hours: What’s Moving Shares After the Dec. 23, 2025 Close—and What to Watch Before Dec. 24’s Open

Pfizer (NYSE: PFE) ended Tuesday’s session (December 23, 2025) lower, then steadied in extended trading as investors digested a late-day safety headline tied to its hemophilia medicine Hympavzi (marstacimab). After-hours snapshot (as of 6:56 p.m. ET): PFE traded around $24.92, up about 0.16% in after-hours action, after closing the regular session at $24.88. Yahoo FinanceDuring Tuesday’s regular session, PFE ranged roughly between $24.84 and $25.34 with volume near 43.7 million shares. Where Pfizer Stock Closed on Dec. 23—and Why the Tape Looked “Holiday Thin” PFE closed down 1.31% at $24.88, snapping a two-day winning streak even as the broader market
24 December 2025
·····
Pfizer Stock (PFE) Update Dec. 23, 2025: Hympavzi Safety Alert, 2026 Guidance, Dividend, and What Analysts Are Watching

Pfizer Stock (PFE) Update Dec. 23, 2025: Hympavzi Safety Alert, 2026 Guidance, Dividend, and What Analysts Are Watching

Dec. 23, 2025 — Pfizer Inc. (NYSE: PFE) stock is ending 2025 in a familiar tug-of-war: a high-yield “value” profile on the one hand, and lingering uncertainty about the company’s post‑COVID growth engine on the other. Shares were trading around $25.15 on Tuesday, keeping the stock in the mid‑$20s range that’s defined much of its recent tape. Today’s news flow adds another variable for investors to price: a safety-related update tied to Pfizer’s hemophilia therapy Hympavzi, landing just as Wall Street digests Pfizer’s newly issued 2026 outlook and the company’s longer road back to growth. What’s moving Pfizer stock on
23 December 2025
·····
Pfizer Stock Outlook for 2026: Oncology Momentum, Obesity Deals, and the Patent Cliff Investors Can’t Ignore

Pfizer Stock Outlook for 2026: Oncology Momentum, Obesity Deals, and the Patent Cliff Investors Can’t Ignore

As of Monday, December 22, 2025, Pfizer (NYSE: PFE) is once again at the center of a familiar market debate: is this a battered pharma giant destined to stay “dead money,” or a dividend-rich turnaround story that could surprise investors as its pipeline matures? The short-term reality is tough to miss. Pfizer has guided to flat-to-down revenue in 2026, with continued COVID-franchise erosion and an accelerating loss-of-exclusivity cycle. But the longer-term case—outlined in a wave of investor and analyst commentary this month—rests on whether Pfizer can execute in the two areas that matter most to its post-patent-cliff future: oncology and
22 December 2025
·····
1 … 4 5 6 7 8 … 10

Stock Market Today

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 07.02.2026

7 February 2026
LIVEMarkets rolling coverageStarted: February 7, 2026, 12:00 AM ESTUpdated: February 7, 2026, 12:49 AM EST CSL Faces Growth Uncertainty Amid Seqirus Spin-off Pause and Flu Vaccine Demand Drop February 7, 2026, 12:49 AM EST. CSL (ASX:CSL) confronts near-term challenges after delaying its Seqirus vaccine unit spin-off due to weaker U.S. flu vaccination uptake, impacting its fiscal 2026 growth outlook. Regulatory scrutiny in Europe over its Tavneos kidney therapy data, plus intensifying U.S. competition for its Vifor iron products, heighten concerns over product credibility and pricing pressure. Despite these headwinds, CSL's diversified portfolio in plasma, vaccines, and kidney therapies underpins its
Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom

Corning stock hits first record close since 2000 as jobs, CPI data loom

7 February 2026
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
Go toTop